Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5552MR)

This product GTTS-WQ5552MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ3592MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13416MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ4014MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ14935MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11146MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ9434MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ9461MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH4102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW